Oxandrolone use causes dyslipidemia in resistance-training practitioners

El uso de oxandrolona causa dislipidemia en practicantes de musculación

O uso de oxandrolona causa dislipidemia em praticantes de musculação

Received: 08/30/2024 | Revised: 09/15/2024 | Accepted: 09/16/2024 | Published: 09/21/2024

Dénis de Lima Greboggy
ORCID: https://orcid.org/0000-0003-3114-7358
Pontifícia Universidade Católica do Paraná, Brazil
E-mail: denis.greboggy@gmail.com

Ericson Pereira
ORCID: https://orcid.org/0000-0002-1449-9004
Pontifícia Universidade Católica do Paraná, Brazil
E-mail: ericson.pereira@pucpr.br

Tiago Franco de Oliveira
ORCID: https://orcid.org/0000-0003-4598-0922
Universidade Federal de Ciências da Saúde de Porto Alegre, Brazil
E-mail: oliveira@ufcspr.edu.br

Thiago Beltrami Dias Batista
ORCID: https://orcid.org/0000-0003-1224-0637
Pontifícia Universidade Católica do Paraná, Brazil
E-mail: tbdbatista@gmail.com

Sarah Eller Franco de Oliveira
ORCID: https://orcid.org/0000-0003-2200-6959
Universidade Federal de Ciências da Saúde de Porto Alegre, Brazil
E-mail: sarahcarobini@hotmail.com

Leticia Birk
ORCID: https://orcid.org/0000-0002-9229-5840
Universidade Federal de Ciências da Saúde de Porto Alegre, Brazil
E-mail: leticiabirk07@gmail.com

Leonardo Cesar Santos de Barros
ORCID: https://orcid.org/0000-0003-4493-4564
Pontifícia Universidade Católica do Paraná, Brazil
E-mail: leonardo_csbarros@hotmail.com

Julia Souto de Jesus
ORCID: https://orcid.org/0000-0002-5217-338X
Pontifícia Universidade Católica do Paraná, Brazil
E-mail: juliasoutodejesus@gmail.com

Pamela Martins
ORCID: https://orcid.org/0000-0001-7217-9888
Pontifícia Universidade Católica do Paraná, Brazil
E-mail: paaamela.martins@hotmail.com

Flavia Auler
ORCID: https://orcid.org/0000-0002-2319-9089
Pontifícia Universidade Católica do Paraná, Brazil
E-mail: flavia.auler@pucpr.br

Maria Heloisa Madruga Chaves
ORCID: https://orcid.org/0000-0003-2696-9824
Pontifícia Universidade Católica do Paraná, Brazil
E-mail: maria.heloisa@pucpr.br

Renata Iani Werneck
ORCID: https://orcid.org/0000-0003-1134-5357
Pontifícia Universidade Católica do Paraná, Brazil
E-mail: renata.iani@pucpr.br

Fernanda Tiboni
ORCID: https://orcid.org/0000-0002-2511-8019
Pontifícia Universidade Católica do Paraná, Brazil
E-mail: fertiboni@hotmail.com

Marlene Maria Tourais de Barros
ORCID: https://orcid.org/0000-0003-0631-4062
Universidade Católica Portuguesa, Portugal
E-mail: mbarros37@gmail.com

1 Pontifícia Universidade Católica do Paraná - Current Address: Imaculada Conceição, 1155, Prado Velho, Curitiba - PR, Brazil. CEP 80215-901.
2 Universidade Federal de Ciências da Saúde de Porto Alegre - Current Address: Rua Sarmento Leite, 245, Centro Histórico, Porto Alegre - RS, Brazil. CEP 90050-170.
3 Universidade Católica Portuguesa - Current Address: Rua d. Diogo Botelho,1327, Porto, Portugal.4169005.
Abstract

Objective: This study investigated blood and salivary parameters in male resistance-training practitioners (RTP) using oxandrolone (OG) and compared with references values and control group (CG), in triplicate. Methods: Blood, saliva, and urine were collected from 22 individuals (OG, n = 11 / CG, n = 11) and analyzed: before oxandrolone (OX) consumption (T1), at cessation of OX use (T2), and three months after cessation of OX use (T3). Complete blood count, lipid profile, metabolites, and enzymes were analyzed from blood samples. Salivary flow, pH, triglycerides, urea, aspartate aminotransferase, alanine aminotransferase, phosphorus, and calcium were analyzed from saliva. Urinalysis was used for toxicological screening. Results: A reduced hdl cholesterol level was observed in the og group (24 mg/dL) compared with the reference value (>40 mg/dL) at T2. HDL levels return to normal after cessation AT T3 (49 mg/dL, >40 mg/dL). A higher triglyceride level (177 mg/dL) was verified in OG group compared with the reference value (<175 mg/dL) at T3. Conclusions: The results of this study suggest that oxandrolone use is associated with changes in lipid profiles, including lower HDL levels and higher triglyceride levels, which are characteristic of dyslipidemia. However, while these findings indicate an association, they do not establish definitive causality. Further research, including well-controlled longitudinal studies, is needed to confirm the causal relationship between oxandrolone use and dyslipidemia.

Keywords: Oxandrolone; Blood; Saliva; Resistance training; Anabolic agents; Dyslipidemia.
1. Introduction

Many individuals make use of anabolic-androgenic steroid (AAS), a synthetic testosterone analog with anabolizing activity. These substances are used therapeutically in different dosages (for example: 20 mg/day for 12 weeks) mainly for maintenance of skeletal muscles and sexual function (Llewellyn’s, 2010; Schroeder et al., 2004).

AAS are indiscriminately used in supraphysiological doses (more than 600 mg/week) for rapid gains in lean mass, rapid loss of body fat and other goals (Cheung & Grossmann, 2018). Among several types of AAS, oxandrolone (OX) is one of the most used with high-frequency use (current and former users) made up 45.8% of one sample (n = 719; n = 329) in resistance-training practitioners (RTP) (Pereira et al., 2019). OX is used to increase performance as well as to improve net protein balance and lean body mass Klinefelter Syndrome, metabolic diseases (Davis et al., 2017a), oral pathologies, and HIV resistance.

These substances are used therapeutically in different dosages (for example: 20 mg/day for 12 weeks) mainly for maintenance of skeletal muscles and sexual function (Llewellyn’s, 2010; Schroeder et al., 2004).

AAS are indiscriminately used in supraphysiological doses (more than 600 mg/week) for rapid gains in lean mass, rapid loss of body fat and other goals (Cheung & Grossmann, 2018). Among several types of AAS, oxandrolone (OX) is one of the most used with high-frequency use (current and former users) made up 45.8% of one sample (n = 719; n = 329) in resistance-training practitioners (RTP) (Pereira et al., 2019). OX is used to increase performance as well as to improve net protein balance and lean body mass Klinefelter Syndrome, metabolic diseases (Davis et al., 2017a), oral pathologies, and HIV treatment (Grunfeld et al., 2006).

Several side effects of AAS (Anabolic-Androgenic Steroids) have been reported, including hypercoagulability, venous and arterial thromboembolism, stroke, ligamentous injuries, and disc herniation. Cardiovascular issues like arrhythmia, as well as liver problems such as steatosis and renal failure, have also been observed. Furthermore, AAS users may experience reproductive system side effects, such as decreased testis volume, suppressed spermatogenesis, infertility, loss of libido, and erectile dysfunction. Additional concerns include gynecomastia, increased LDL (low-density lipoprotein), decreased HDL (high-density lipoprotein), increased triglycerides, increased cholesterol, decreased HDL cholesterol, and increased risk of cardiovascular disease (Arbuckle et al., 1999).

2. Methods

Métodos: Se recolectaron sangre, saliva y orina de 22 individuos (OG, n = 11 / GC, n = 11) y se analizaron: antes del consumo de oxandrolona (OX) (T1), al cese del uso de OX (T2) y tres meses después del cese del uso de OX (T3). Se analizaron hemograma completo, perfil lipídico, metabolitos y enzimas a partir de muestras de sangre. A partir de la saliva se analizaron el flujo salival, el pH, los triglicéridos, la urea, la aspartato aminotransferasa, la alanina aminotransferasa, fósforo y calcio. Se utilizó análisis de orina para el cribado toxicológico. Resultados: Se observó una reducción del nivel de colesterol HDL en el grupo OG (24 mg/dL) en comparación con el valor de referencia (>40 mg/dL) en T2. Los niveles de HDL vuelven a la normalidad después de suspender el tratamiento en T3 (49 mg/dL, >40 mg/dL). Se verificó un nivel de triglicéridos más alto (177 mg/dL) en el grupo OG en comparación con el valor de referencia (<175 mg/dL) en T3. Conclusiones: Los resultados de este estudio sugieren que el uso de oxandrolona se asocia con cambios en los perfiles lipídicos, incluidos niveles más bajos de HDL y niveles más altos de triglicéridos, que son característicos de la dislipidemia. Sin embargo, si bien estos hallazgos indican una asociación, no establecen una causalidad definitiva. Se necesitan más investigaciones, incluidos estudios longitudinales bien controlados, para confirmar la relación causal entre el uso de oxandrolona y la dislipidemia.

Palavras-chave: Oxandrolona; Sangue; Saliva; Musculação; Agentes anabólicos; Dislipidemia.
(high-density lipoprotein), and hormonal imbalances like reduced luteinizing hormone (LH), follicle-stimulating hormone (FSH), and blood testosterone levels.

Moreover, AAS use can elevate liver enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST). In those using AAS, basal blood tests often show increased hemoglobin, high white blood cell and neutrophil counts, and elevated C-reactive protein (CRP) levels (Hartgens & Kuipers, 2004a). These side effects may lead to costly treatments, ultimately posing a significant burden on public health (Horwitz et al., 2019).

While various biochemical parameters are evaluated in the blood, they are also measured from the saliva, a non-invasive method. Some substances can alter parameters, such as salivary flow reduction observed with use of hypoglycemic drugs antidepressants, hypothyroidism, or contraceptives (Castro-Silva et al., 2017). Other effects are also observed, such as increased pH from green tea consumption, decrease in salivary pH in crack cocaine users (Woyceichoski et al., 2013) and elevated alanine aminotransferase (ALT) in patients with kidney disease (Alpdemir et al., 2018). Even though, these studies evaluate different drugs and conditions, none has verified the salivary effect of OX. As far as we currently know, there are no studies that have aimed to verify blood and salivary effects in AAS users using only AAS (confirmation by urine screening). Furthermore, several studies do not measure AAS used by urinalysis; doses are self-reported, but not compared with reference values.

The primary purpose of this study was to verify the effects of OX on blood and saliva compared with reference values, and to compare parameters before, immediately after, and three months after volunteers had finished the OX cycle.

The article has already been published as a preprint on Research Square with the following registration: https://doi.org/10.21203/rs.3.rs-50105/v1. The title is "Oxandrolone Use Causes Dyslipidemia in Resistance Training Practitioners," and it is available at https://assets-eu.researchsquare.com/files/rs-50105/v1/f4fc94e5-1f25-4f9c-86d3-72980046dd60.pdf?c=1631850727

2. Methods

Study Design

According to Gil (2017), this is a prospective, analytical, observational study of a comparative, quantitative nature.

Ethical Procedures

The project was approved by the Ethics and Research Committee of the Pontifical Catholic University of Paraná under protocol number 2.556.109 and followed the STROBE Statement guideline. All participants signed an appropriate informed consent paperwork. The study was conducted with a high ethical standard, even when formal approval has been obtained.

Inclusion and exclusion criteria

Subjects were recruited through the dissemination of research on social networks, websites, WhatsApp, and the snowball technique. Information about volunteers from resistance-training programs was included in the study. Requirements were: male, expressed intention of OX use, six months in AAS washout or never used AAS, and self-report of no drug treatment or history of cardiovascular, respiratory, hepatic, renal, musculoskeletal, or metabolic disorders. This study included individuals who participated in a resistance-training program in the six months before the beginning of the evaluations.

Those individuals who did not complete one or more stages of the study were excluded from the research. Other exclusion criteria were: any illness acquired during the training period and collections that interfered with the results; psychotropic drug use; consumption of more than 15 alcoholic beverages per week (≈ 30 g/day); fixed or mobile orthodontic
braces, removable total or partial denture or fixed denture; and smoking. All of these factors can interfere with saliva production.

Sample selection

Thirty-seven male subjects were initially recruited by social networks via the snowball method. The researcher was approached by subjects (by telephone) who intended to use OX, while the 26 subjects in the CG contacted the researcher. Forty-four subjects attended a personal interview, during which it was explained that no one, at no time, would provide any AAS substance, and that information on the time of use or dosages was likewise not to be prescribed. Participants gave their consent to participate under these conditions. Finally, 22 individuals remained in the study; reasons dropping out are shown in Figure 1. We can observe some subjects dropped out from the research or, were excluded because they used AAS other than OX.

It was collected information about age, weight, height, body mass index, total time (years) and frequency (days/week) of resistance-training practice, as well as training session time per week (minutes/day) (Table 1).
Table 1 - Anthropometrics and training characteristics among OG and CG (columns).

| Anthropometrics and Training characteristics | OG (n=11) | CG (n=11) |
|---------------------------------------------|-----------|-----------|
| Age (year)                                  | 27.5(±6.6) | 23.7(±2.8) |
| Weight (kg)                                 | 87.2(±13.8) | 76.0(±10.9) |
| Height (m)                                  | 1.78(±0.05) | 1.76 (±0.04) |
| BMI (kg/m²)                                 | 27.3(±3.4) | 24.4(±2.6) |
| Total RT practice (year)                    | 6.3(±1.7)  | 5.2(±3.4)  |
| RT frequency (days/week)                    | 4.7(±1.0)  | 4.0(±1.3)  |
| Training session time (min)                 | 67.7(±31.4) | 59.0(±12.2) |

Notes: SD: Stand Deviation; RT = Resistance Training; BMI = Body Mass Index. Source: Authors.

Among OX users, all used an oral form, and dosages varied from 0.04 to 0.97 mg/kg (from 4 to 12 weeks, mean = 7.4 SD ± 2.2) (Table 2) with no participant having a similar pattern of use. Twenty-two subjects participated in all stages of the study: 11 OG and 11 CG. It is important remembering that at no time any subject was instructed regarding the amount, frequency, and time of OX use. All subjects seek the investigator of free desire. Nine (n = 9) individuals acquired AAS in drugstores, and two (n = 2) purchased the product via the Internet, ready to use and with registered trademarks.

Table 2 - Individual oxandrolone use (OG), according to self-report.

| Subjects | Min. OX (mg/kg/day) | Max. OX (mg/kg/day) | Weight (kg) | Weeks |
|----------|---------------------|---------------------|-------------|-------|
| 1        | 0.75                | 1.00                | 80          | 7     |
| 2        | 0.73                | 0.73                | 82          | 9     |
| 3        | 0.39                | 0.39                | 103         | 9     |
| 4        | 0.47                | 0.47                | 85.5        | 7.5   |
| 5        | 0.47                | 0.47                | 84.6        | 7.5   |
| 6        | 0.50                | 0.50                | 80          | 7     |
| 9        | 0.51                | 0.51                | 79          | 4.5   |
| 8        | 0.56                | 0.56                | 72          | 6     |
| 9        | 0.24                | 1.20                | 83.5        | 4     |
| 10       | 0.16                | 0.66                | 122         | 12    |
| 11       | 0.06                | 0.45                | 88.4        | 8     |

Ox: oxandrolone; min: minimum; max: maximum. Calculations based on volunteers' self-report. Source: Authors.

Sample collection timepoints

Samples were collected and analyzed at three timepoints. For the OG, these timepoints were: T1, before drug use; T2, after OX use (mean of 7.4 SD 2.2 weeks); and T3, three months after use, as previously indicated (Hartgens et al., 2004). Samples from the CG were collected at T1 in the same week as the OG, and T2 was collected eight weeks later, according to previous study. The collection of CG T3 occurred three months after T2. Blood, saliva, and urine were all collected from 2 pm to 5 pm.
Blood collection and analyses

Blood collection took place in the Biochemistry Laboratory at the School of Life Sciences located in the Pontifical Catholic University of Paraná. There was no indication of fasting. A nurse collected blood by radial artery puncture, and it was processed on the same day. Plasma biochemical analyses were performed on an AU480 Chemistry Analyzer (Beckman Coulter, Pasadena, CA), except for glucose measurement, which was performed using the Cobas Mira Plus device (Roche Diagnostic Systems, Basel, Switzerland). The reagents used were analysis-grade (Kovalent, São Gonçalo, Brazil). Hormones were measured on the UniCel DxI 800 Access Immunoassay System (Beckman Coulter, Pasadena, CA), and blood count on the Coulter LH 750 Hematology Analyzer (Beckman Coulter, Pasadena, CA). Hemogram included: erythrocytes, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), red blood cell distribution width (RDW), leukocytes, basophils, eosinophils, band neutrophils, segmented neutrophils, lymphocytes, monocytes and platelets (Table 3 - Hemogram). We also observed glucose, follicle-stimulating hormone (FSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), total testosterone, total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, estradiol, c-reactive protein (CRP), urea, amylase, albumin, calcium, creatinine, alkaline phosphatase (ALP), phosphorus and aspartate transaminase (AST), alanine aminotransferase (ALT) (Table 4. Biochemical analysis).

Saliva collection and analyses

Saliva was collected by masticatory stimulation using a 1 cm sterile piece of rubber stimulator, with for 1 minute for oral self-cleaning and 5 minutes for chewing. All saliva produced was captured in an 80 ml universal collection flask and immediately assessed for pH with a digital pH-meter (Digimed, Analytical Instrumentation, model DM 20, São Paulo, Brazil). Sialometry was obtained by the gravimetry method. Samples were weighed with a precision analytical balance (Gehaka AG-200, São Paulo, Brazil). The calculated salivary flow is represented in mL per minute. For preparation and storage, samples were centrifuged at 2000 g for 5 minutes at room temperature to remove debris. The supernatant was separated and frozen until the time of analysis.

The equipment used for sialochemical analysis was the Cobas Mira Plus (Roche Diagnostic Systems, Basel, Switzerland). Bioclin reagents (Bioclin/Quibasa, Belo Horizonte, Brazil) were also used for analysis. The methodology followed was according to the manufacturer's recommendations. The sensitivity and method linearity are described in Supplementary Table 1. Salivary variables evaluated were salivary flow, pH, triglycerides, urea, AST, alanine aminotransferase (ALT), phosphorus, and calcium (Table 5).

Urine collection and AAS Screening

Urine samples were self-collected and analyzed liquid chromatography system coupled to a quadrupole time-of-flight mass spectrometer (LC-QTOF) to quantify oxandrolone (OX) for the three timepoints of the study. We also detected other AAS (Supplementary Text 1)

Statistical analysis

For statistical analysis, data normality was assessed using the Shapiro-Wilk test; where the data did not present a normal distribution, nonparametric statistics were used. Mann-Whitney U and chi-square tests were performed to compare anthropometric, demographic, blood, salivary, and urine variables between groups. On timepoints within groups, Friedman test followed Wilcoxon peer comparison were made. The p-value adopted was < 0.05. The software used was IBM SPSS 25.0 for Windows.
3. Results

In comparisons among groups (OG X CG) at the three timepoints (T1, T2, and T3), significant increased OG hemogram were found for: band neutrophils at T2, monocytes at T1 and platelets at T1 and T2. When blood variables were compared between timepoints (T1 x T2; T2 x T3; T1 x T3) within each treatment group separately, OG showed: hemoglobin count reduced from T1 to T2 (Table 3).

Table 3 - Hemogram comparison groups (columns), within times (rows) and reference values.

| VARIABLES       | TIMES | MEDIAN OG (n=11) | MEDIAN CG (n=11) | REFERENCE VALUE (Bick, 1993) |
|-----------------|-------|-----------------|-----------------|-----------------------------|
| Erythrocytes    |       |                 |                 |                             |
| T1              | 5.30a | 5.36a           | 4.60 – 6.20 µL  |
| T2              | 5.07a | 5.20b           |                 |
| T3              | 5.12a | 5.47b           |                 |
| Hemoglobin      |       |                 |                 |                             |
| T1              | 15.90a| 15.70c          | 14.0 – 18.0 g/dL|
| T2              | 15.60b| 15.80b          |                 |
| T3              | 15.60b| 16.40c          |                 |
| Hematocrit      |       |                 |                 |                             |
| T1              | 45.10a| 48.50a          | 40.0 – 54.0 mL/dL|
| T2              | 45.10a| 45.50b          |                 |
| T3              | 45.10a| 47.30b          |                 |
| MCV             |       |                 |                 |                             |
| T1              | 86.90a| 88.81a          | 80.0 – 96.0 mL  |
| T2              | 86.80a| 87.82ab         |                 |
| T3              | 86.69a| 87.31b          |                 |
| MCH             |       |                 |                 |                             |
| T1              | 29.51 | 29.77           | 26.0 – 34.0 pg  |
| T2              | 29.78 | 30.18           |                 |
| T3              | 30.47 | 30.19           |                 |
| R.D.W.          |       |                 |                 |                             |
| T1              | 12.80 | 13.30           | 11.0 – 14.5 %   |
| T2              | 13.20 | 13.00           |                 |
| T3              | 12.90 | 12.70           |                 |
| Leukocytes      |       |                 |                 |                             |
| T1              | 7.000,00a| 6.700,00a| 3.600 – 11.000 µL |
| T2              | 6.900,00a| 6.445,00b| /µL             |
| T3              | 7.200,00a| 7.500,00c| /µL             |
| Basophils       |       |                 |                 |                             |
| T1              | 0,00  | 0,00            | 0 – 100 /µL     |
| T2              | 44    | 46,00           |                 |
| T3              | 0,00  | 0,00            |                 |
| Eosinophils     |       |                 |                 |                             |
| T1              | 146,00| 138,00          | 50 – 400 /µL    |
| T2              | 124,00| 164,00          |                 |
| T3              | 216,00| 97,00           |                 |
| Band neutrophils|      |                 |                 |                             |
| T1              | 70,00a| 79,00a          | 0 – 700 /µL     |
| T2              | 69,00,a| 46,00,00b| /µL             |
| T3              | 72,00a| 75,00,00c| /µL             |
| Segmented       |       |                 |                 |                             |
| neutrophils     |       |                 |                 |                             |
| T1              | 4.218,00a| 4.187,00a| 1.400 – 6.600 µL |
| T2              | 3.933,00a| 3.692,00b| /µL             |
| T3              | 3.762,00a| 3.740,00b| /µL             |
| Lymphocytes     |       |                 |                 |                             |
| T1              | 2.075,00| 2.415,00| 1.200 – 3.200 /µL |
| T2              | 2.070,00| 2.067,00| /µL             |
| T3              | 2.025,00| 2.130,00| /µL             |
| Monocytes       |       |                 |                 |                             |
| T1              | 490,00,a| 232,00,b| 300 – 900 /µL   |
| T2              | 504,00a| 516,00b| /µL             |
| T3              | 574,00a| 497,00b| /µL             |
| Platelets       |       |                 |                 |                             |
| T1              | 268,000,00a| 212,000,00ba| 150,000 – 450,000 /µL |
| T2              | 269,000,00a| 207,000,00b| /µL             |
| T3              | 238,000,00a| 211,111,00ac| /µL             |

Uppercase letters represent differences in time between groups by Mann-Whitney U test.
Lowercase letters represent differences between the moments in both groups by Wilcoxon test 2x2 comparison; Median values without letters mention the absence of any statistically significant difference. Source: Authors.
Concerning reference values, the OG presented a higher HDL level at T2, returning to normal levels at T3, and a triglyceride level that remained within a typical value range at T1 and T2, but was above this range at T3.

There were groups (OG X CG) at the three timepoints (T1, T2, and T3), significant increased LH at T1 and triglycerides at T2 and T3. In contrast, some variables showed a reduction in OG: total testosterone at T2 and T3, calcium at T3, and ALP at T1 and T2. When blood variables were compared among timepoints (T1 x T2; T2 x T3; T1 x T3) within each treatment group separately, OG showed: FSH increased from T1 to T3; HDL increased from T2 to T3; triglycerides increased from T1 and T2 to T3; estradiol increased from T1 and T2 to T3; calcium reduced from T1 and T2 to T3 (Table 4).

Table 4 - Blood variables comparison groups (columns), within times (rows) and reference values.

| VARIABLES     | MEDIAN OG (n=11) | MEDIAN CG (n=11) | REFERENCE VALUE* |
|---------------|------------------|------------------|------------------|
| Glucose       |                  |                  |                  |
| T1            | 73,00            | 72,00            | 65 – 99 (mg/dL)  |
| T2            | 86,00            | 83,00            | (Oliveira et al., 2018)* |
| T3            | 85,00            | 81,00            |                  |
| FSH           |                  |                  |                  |
| T1            | 3,38*            | 3,01*            | 1,27 – 19,26 (mUI/mL) (Beckman Coulter, 2020)* |
| T2            | 4,41*            | 4,91*            |                  |
| T3            | 4,36*            | 4,78*            |                  |
| LH            |                  |                  |                  |
| T1            | 4,26A            | 3,00B            | 1,24 – 8,62 (mUI/mL) (Beckman Coulter, 2020)* |
| T2            | 3,35             | 4,70             |                  |
| T3            | 5,22             | 4,35             |                  |
| ACHT          |                  |                  |                  |
| T1            | 22,00            | 16,00            | < 46,0 (pg/mL)   |
| T2            | 16,90            | 17,10            | (Siemens Healthcare Diagnósticos S.A., 2020)* |
| T3            | 21,40            | 16,30            |                  |
| Total Testosterone |          |                  | 175,00 – 781,00 (ng/dL) (Beckman Coulter, 2020)* |
| T1            | 358,45           | 414,23           |                  |
| T2            | 240,94A          | 414,35B          |                  |
| T3            | 295,56A          | 489,81B          |                  |
| Total cholesterol |            |                  |                  |
| T1            | 183,00           | 154,00           | < 190 (mg/dL)    |
| T2            | 185,00           | 150,00           | (Scartezini et al., 2017)* |
| T3            | 159,00           | 143,00           |                  |
| HDL †         |                  |                  |                  |
| T1            | 47,00*           | 50,00*           | >40 (mg/dL) (Scartezini et al., 2017)* |
| T2            | 24,00*           | 45,00*           |                  |
| T3            | 49,00*           | 47,00*           |                  |
| LDL           |                  |                  |                  |
| T1            | 102,00           | 95,00            | < 130 (mg/dL)    |
| T2            | 111,00           | 91,00ab          | (Scartezini et al., 2017)* |
| T3            | 101,00           | 79,00            |                  |
| Triglycerides ‡ |      |                  |                  |
| T1            | 133,00           | 75,00*           | < 175 (mg/dL)    |
| T2            | 91,00*           | 69,00ab          | (Scartezini et al., 2017)* |
| T3            | 177,00*          | 90,00*           |                  |
| Estradiol     |                  |                  |                  |
| T1            | 20,00           | 20,00           | < 47 (pg/mL)     |
| T2            | 23,00           | 21,00           | (Pierre & Ciriades, 2009)* |
| T3            | 39,00           | 34,00           |                  |
| CRP           |                  |                  |                  |
| T1            | 0,67a           | 0,32a           | < 5,00 (mg/L)    |
| T2            | 0,56a           | 0,53b           | (Pearson et al., 2003)* |
| T3            | 0,70a           | 0,51ab          |                  |
| Urea          |                  |                  |                  |
| T1            | 42,00           | 39,00           | 17 – 43 (mg/dL)  |
| T2            | 42,00           | 36,00           | (Pierre & Ciriades, 2009)* |
| T3            | 39,00           | 40,00           |                  |
| Amylase       |                  |                  |                  |
| T1            | 49,00           | 62,00           | 22 – 80 (U/L)    |
| T2            | 52,00           | 67,00           | (Basilio et al., 2016)* |
| T3            | 53,00           | 57,00           |                  |
| Albumin       |                  |                  |                  |
| T1            | 4,90            | 4,90           | 3,5 – 5,2 (g/dL) |
| T2            | 4,90            | 5,00           | (Beckman Coulter, 2020)* |
| T3            | 4,70            | 4,80           |                  |
Calcium\[\text{T1} 9,80^{a}\]
\[\text{T2} 9,60^{a}\]
\[\text{T3} 9,30^{ab}\]
\[8,9 – 10,7 \text{ (mg/dL)} \] (Pierre & Ciriades, 2009)*

Creatinine
\[\text{T1} 1,03\]
\[\text{T2} 1,12\]
\[\text{T3} 1,03\]
\[0,90 – 1,30 \text{ (mg/dL)} \] (Pierre & Ciriades, 2009)*

ALP
\[\text{T1} 56,00^{a}\]
\[\text{T2} 49,00^{a}\]
\[\text{T3} 57,00\]
\[30 – 120 \text{ (U/L)} \] (Beckman Coulter, 2020)*

Blood phosphorus
\[\text{T1} 3,60\]
\[\text{T2} 3,90\]
\[\text{T3} 3,90\]
\[2,7 – 4,5 \text{ (mg/dL)} \] (Wu, 2006)*

AST
\[\text{T1} 26,00\]
\[\text{T2} 27,00\]
\[\text{T3} 26,00\]
\[< 50 \text{ (U/L)} \] (Beckman Coulter, 2020)*

ALT
\[\text{T1} 26,00\]
\[\text{T2} 34,00\]
\[\text{T3} 28,00\]
\[< 50 \text{ (U/L)} \] (Beckman Coulter, 2020)*

For salivary variables, only the pH in OG was decreased, at T3 (Table 5).

### Table 5 - Salivary variables comparison groups (columns) within times (rows)

| VARIABLES     | MEDIAN OG (n=11)* | MEDIAN CG (n=11)* |
|---------------|-------------------|-------------------|
| Salivary flow |                   |                   |
| T1            | 0,82              | 1,11              |
| T2            | 0,95              | 1,22              |
| T3            | 1,09              | 1,17              |
| T1            | 7,68              | 7,66              |
| T2            | 7,88              | 7,67              |
| T3            | 7,50^{a}          | 7,84^{b}          |
| Triglycerides |                   |                   |
| T1            | 5,00              | 2,58              |
| T2            | 2,58              | 2,58              |
| T3            | 2,58              | 2,58              |
| Urea          |                   |                   |
| T1            | 30,40             | 26,30             |
| T2            | 23,40             | 20,90             |
| T3            | 25,90             | 22,40             |
| AST           |                   |                   |
| T1            | 14,00             | 12,00             |
| T2            | 15,00             | 8,00              |
| T3            | 9,00              | 9,00              |
| ALT           |                   |                   |
| T1            | 3,00              | 2,00              |
| T2            | 4,00              | 3,00              |
| T3            | 0,99              | 0,99              |
| Phosphorus    |                   |                   |
| T1            | 0,48^{a}          | 0,53^{ab}         |
| T2            | 0,35^{b}          | 0,23^{a}          |
| T3            | 0,51^{a}          | 0,38^{b}          |

Median values without letters mention the absence of any statistically significant difference. *Reference values for the saliva variables there are no consensus on literature or standardized methodologies. Source: Authors.
4. Discussion

This study explored the effects of OX on blood and saliva compared with reference values during and after the OX cycle. To our knowledge, this is the first study that evaluated blood and salivary parameters in RTP that used only OX validated by urine screening.

Despite the alteration on lipidic profile by several AAS concomitant use has been established in the literature (Arazi, 2018), concerning the only use of OX, we found reducing levels of HDL cholesterol shortly after use of OX, returning to normal after three months.

According to (Bates et al., 2019), low levels of HDL cholesterol, as well as high levels of triglycerides and LDL cholesterol, are important risk factors for cardiovascular disease. Considering only HDL cholesterol, our results indicate the effect of OX use can be returned after three months washout. Despite HDL returning to normal, users had hypertriglyceridemia three months after using OX. These data point to dyslipidemia in OX users.

In a previous study (Cheung et al., 1980) OX was tested as a cholesterol-lowering drug. The authors proposed 7.5 mg/day for three months, followed by two months washout showed HDL decreased significantly. An investigation focusing on metabolic syndrome, used 10 mg/day oral OX doses for one week and found reductions in HDL levels with marked increases in hepatic ketogenesis, increasing influx fatty acids into the liver. Other paper proposed Klinefelter syndrome treatment, with oral OX 0.06 mg/kg/day (therapeutic purpose) or placebo for two years, HDL was lowered (Davis et al., 2017). A study with HIV-infected men that was not controlled antiretroviral intake treated with OX daily for 12 weeks reduced HDL for all doses of OX used (Grunfeld et al., 2006).

Although high AAS doses are used for short periods of time, many athletes abuse these ones, self-administering doses up to 100-and even 1000-fold, more than safe doses, producing circulating testosterone levels two to three orders of magnitude above healthy male reference range, often for prolonged periods (Graham et al., 2008). The maximal anabolic dose of testosterone is not known, but almost certainly vastly exceeds 600 mg of testosterone a week (Cheung & Grossmann, 2018). Excess AAS dose cause dyslipidemia secondary, increasing total cholesterol, create no changes in triglycerides, and decrease HDL (Souza et al., 2019). In the present study, we were unable to determine the exact dose of OX used by the volunteers, but we suggest that they were supraphysiological doses, and that they caused a consistent effect of OX on HDL production.

Other lipid profile variable we observed was triglyceride, which remained high. This point is important, as the scientific literature points to the AAS action on fat metabolism (Rosca et al., 2019) and can promote negative impacts on the cardiovascular system.

In an animal model, OX elevated triglycerides, reduced HDL, decreased hepatic triglycerides, and increased levels of non-esterified fatty acids produced by the liver. This could possibly lead to increased lipid synthesis of hepatic triglycerides (Rosca et al., 2019). Additionally, OX may reduce blood triglycerides by activating triglyceride lipase, which results in the hydrolysis of peripheral triglycerides. However, once the intake of OX ceases, triglycerides tend to increase (Glueck et al., 1973).

For comparison, we used Brazilian reference values for triglycerides in this study. The results indicate a significant increase, almost to the borderline level, posing a risk for cardiovascular disease after stopping OX use (Oliveira et al., 2018). According to WHO classification, individuals with triglyceride levels higher than 180 mg/dL are considered at risk for cardiovascular disease.

Furthermore, the results for triglycerides in this study align with findings from other research, showing increased lipolysis and the release of free fatty acids with OX use. However, three months after discontinuing OX, triglyceride levels remained above the reference standards. This contradictory result may be explained by factors such as varying OX doses,
different monitoring periods, resistance exercise practices, duration of use, cycle types, and other variables. It is possible that a washout period of three or more months could bring these parameters back to normal (Hartgens & Kuipers, 2004).

Our research also observed some hemogram variation in hemoglobin, band neutrophils, monocytes and platelets (note Table 4). Assessed components were within the reference limits described in the consolidated literature as well blood variables (triglyceride exception at T3).

Despite this, our research presents relevant methodological criteria that were used in the study: comparison with reference values and the detection urine screening, among others. Studies show that the AAS cycle (duration use) can last from 10 to 12 weeks (Llewellyn’s, 2010) close to the timeframe of this study. It is important that we evaluated a single, isolated AAS.

Limitations of our study must be considered. The results found in our study were different from the studies mentioned above, perhaps because they did not follow the subjects several months after ending the use of AAS. We did not make a standardized dose, or limit cycles, because OX is a controlled substance, and its prescription is made only by physicians.

5. Conclusions

Oxandrolone users had a reduction in HDL levels after ending the use of OX, returning to reference values three months ending the use of OX, which was not observed for triglycerides, which remained high. The results of this study suggest that oxandrolone use is associated with changes in lipid profiles, including lower HDL levels and higher triglyceride levels, which are characteristic of dyslipidemia. However, while these findings indicate an association, they do not establish definitive causality. Further research, including well-controlled longitudinal studies, is needed to confirm the causal relationship between oxandrolone use and dyslipidemia.

References

Alpdemir, M., Eryilmaz, M., Alpdemir, M. F., Topçu, G., Azak, A., & Yücel, D. (2018). Comparison of Widely Used Biochemical Analytes in the Serum and Saliva Samples of Dialysis Patients. Journal of Medical Biochemistry, 37(3), 346–354. https://doi.org/10.1515/jomb-2017-0056

Arazi, H. (2018). Effects of longitudinal abuse of anabolic steroids on liver enzymes activity and lipid profiles of male bodybuilders. Progress in Nutrition, 20(3), 323–328. https://doi.org/10.21375/pn.v20i3.5287

Graham, M. R., Davies, B., Grace, F. M., Kicman, A., & Baker, J. S. (2008). Anabolic steroid use: patterns of use and detection of doping. Sports medicine, 38(6), 505–525. https://doi.org/10.2165/00007256-200838060-00005

Basílio, I. L. D., Matos, A. P. R., Parente, G. V. U., & Oliveira, J. M. (2016). Análise do líquido ascítico de pacientes portadores de doença hepática. Revista Saúde e Câncer, 5(1), 23–36. DOI missed: https://doi.org/10.35572/esc.v5i1.201

Bates, G., Van Hout, M. C., Teck, J. T. W., & McVeigh, J. (2019). Treatments for people who use anabolic androgenic steroids: a scoping review. Harm Reduction Journal, 16(1), 75. https://doi.org/10.1186/s12954-019-0343-1

Beckman Coulter, Inc. (2020). Beckman Coulter, Inc. https://www.beckmancoulter.com/En/Support. https://www.beckmancoulter.com/

Bick, (1993). Hematology: clinical and laboratory practice (R. L. Bick, Ed.). Mosby Inc.

Castro-Silva, I. L., Carvalho, M. A. F., Basílio, S. R., Farias Júnior, M. V. M., & Maciel, J. A. C. (2017). Relação Entre Alterações Salivares E Terapia Medicamentosa Em Adultos Jovens : Um Estudo Transversal Relation Between Salivary Alterations and Drug Therapy in Young Adults : a Cross - Sectional Study. Brazilian Journal of Surgery and Clinical Research, 18(2), 17–24.

Cheung, A. S., & Grossmann, M. (2018). Physiological basis behind ergogenic effects of anabolic androgens. Molecular and Cellular Endocrinology, 464, 14–20. https://doi.org/10.1016/j.mce.2017.01.047

Cheung, M. C., Albers, J. J., Wahl, P. W., & Hazzard, W. R. (1980). High density lipoproteins during hypolipidemic therapy. A comparative study of four drugs. Atherosclerosis, 35(3), 215–228. https://doi.org/10.1016/0021-9150(80)90121-5

Davis, S. M., Cox-Martin, M. G., Bardsley, M. Z., Kowal, K., Zeitler, P. S., & Ross, J. L. (2017a). Effects of oxandrolone on cardiometabolic health in boys with klinefelter syndrome: A randomized controlled trial. Journal of Clinical Endocrinology and Metabolism, 102(1), 176–184. https://doi.org/10.1210/jc.2016-2904

Gil, A. C. (2017). Como elaborar projetos de pesquisa. 6 ed. Atlas.
Glueck, C. J., Ford, S., Steiner, P., & Fallat, R. (1973). Triglyceride removal efficiency and lipoprotein lipases: Effects of oxandrolone. *Metabolism, 22*(6), 807–814. https://doi.org/10.1016/0026-0495(73)90051-6

Grunfeld, C., Kotler, D. P., Dobs, A., Glesby, M., & Blusin, S. (2006). Oxandrolone in the treatment of HIV-associated weight loss in men: A randomized, double-blind, placebo-controlled study. *Journal of Acquired Immune Deficiency Syndromes, 41*(3), 304–314. https://doi.org/10.1097/01.qai.0000197546.56131.40

Hartgens, F., & Kuipers, H. (2004a). Effects of androgenic-anabolic steroids in athletes. *Sports Medicine, 34*(8), 513–554. https://doi.org/10.2165/00007256-20043408-00003

Hartgens, F., Rietjens, G., Keizer, H. A., Kuipers, H., & Wolffensbuttel, B. H. R. (2004). Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). *British Journal of Sports Medicine, 38*(3), 253–259. https://doi.org/10.1136/bjsm.2003.000199

Horwitz, H., Andersen, J. T., & Dalhoff, K. P. (2019). Health consequences of androgenic anabolic steroid use. *Journal of Internal Medicine*, 285(3), 333–340. https://doi.org/10.1111/joim.12850

Llewellyn’s, W. (2010). *Anabolics* (10th ed.). Molecular Nutrition.

Oliveira, J. E. P. O., Montenegro Júnior, R. M., Júnior, R. M. M., & Vencio, S. (2018). *Diretrizes da Sociedade Brasileira de Diabetes* 2017-2018. https://edisciplinas.usp.br/pluginfile.php/4925460/mod_resource/content/1/diretrizes-sbd-2017-2018.pdf

Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., Rifai, N., Smith, S. C., Taubert, K., Tracy, R. P., & Vinicor, F. (2003). Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. *Circulation, 107*(3), 499–511. https://doi.org/10.1161/01.CIR.0000052939.59093.45

Pereira, E., Moyses, S. J., Ignácio, S. A., Mendes, D. K., Da Silva, D. S., Carneiro, E., Hardy, A. M. T. G., Rosa, E. A. R., Bettega, P. V. C., & Johann, A. C. B. R. (2019). Anabolic steroids among resistance training practitioners. *PLoS ONE, 14*(10), 1–13. https://doi.org/10.1371/journal.pone.0223384

Pierre, G., & Ciriades, J. (2009). *Manual de Patologia Clínica - Ciriades*. Atheneu.

Rosca, A. E., Stancu, C. S., Badiu, C., Popescu, B. O., Mirica, R., Câruntu, C., Gologan, S., Voiculescu, S. E., & Zagrean, A. M. (2019). Lipid profile changes induced by chronic administration of anabolic androgenic steroids and taurine in rats. *Medicina (Lithuania), 55*(9). https://doi.org/10.3390/medicine55090540

Scartezini M, Ferreira CES, Izar MCO, Bertoluci M, Vencio S, Campana GA, et al. Posicionamento sobre a Flexibilização do Jejum para o Perfil Lipídico. *Arq Bras Cardiol*. 2017; 108(3):195-197. https://doi.org/10.5935/abc.20170039

Schroeder, E. T., Zheng, L., Yarasheski, K. E., Qian, D., Stewart, Y., Flores, C., Martinez, C., Terk, M., & Sattler, F. R. (2004). Treatment with oxandrolone and the durability of effects in older men. *Journal of Applied Physiology, 96*(3), 1055–1062. https://doi.org/10.1152/japplphysiol.00808.2003

Siemens Healthcare Diagnósticos S.A. (2020). *Siemens Healthcare Diagnósticos*. https://www.siemens-healthineers.com/br/Support-Documentation/Online-Services/Document-Library. https://www.siemens-healthineers.com/br

Souza, F. R. de, Dos Santos, M. R., Porello, R. A., Fonseca, G. W. P. da, Sayegh, A. L. C., Lima, T. P., Ferreira, F. D., Oliveira, T. F. de, Yonamine, M., Takayama, L., Pereira, R. M. R., Negrão, C. E., Passarelli, M., Rochitte, C. E., & Alves, M. J. de N. N. (2019). Diminished cholesterol efflux mediated by HDL and coronary artery disease in young male anabolic anabolic steroid users. *Atherosclerosis, 283*, 100–105. https://doi.org/10.1016/j.atherosclerosis.2019.02.006

Woyciechowski, I. E. C., Costa, C. H., de Araújo, C. M., Brancher, J. A., Resende, L. G., Vieira, I., & de Lima, A. A. S. (2013). Salivary buffer capacity, pH, and stimulated flow rate of crack cocaine users. *Journal of Investigative and Clinical Dentistry*, 4(3), 160–163. https://doi.org/10.1111/j.2041-1626.2012.00126.x

Wu, A. H. B. (2006). *Tietz Clinical Guide to Laboratory Tests*. https://books.google.com/books?hl=en&lr=&id=aQqjBQAAQBAJ&pgis=1